Last reviewed · How we verify

Paralytic Ileus Prevention — Treatment Landscape & Competitive Intelligence

Paralytic Ileus Prevention (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Paralytic Ileus Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Infuvite Adult DEXPANTHENOL Pfizer dexpanthenol 1953-01-01
Bepanthen Bepanthen RWTH Aachen University

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Paralytic Ileus Prevention
  2. RWTH Aachen University · 1 drug in Paralytic Ileus Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Paralytic Ileus Prevention:

Cite this brief

Drug Landscape (2026). Paralytic Ileus Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/paralytic-ileus-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing